title: The effects of interferon beta-1a on proton MR spectroscopic imaging in patients with multiple sclerosis, a controlled study, preliminary results.
abstract: To evaluate the effects of interferon beta-1a(INFbeta-1a) on brain metabolites in patients with multiple sclerosis (MS), we performed Magnetic Resonance Spectroscopy Imaging (MRSI) on five patients treated with INFbeta-1a (Rebif 44 microg), and on five untreated patients. Six healthy volunteers were used as controls. Patients were evaluated at the beginning, in the first, third, sixth, and twelfth month. There were no significant differences in normal appearing white matter (NAWM) metabolite peaks of the control group and patients with MS. However, in white matter lesions (WML) and NAWM there was significant differences between the basal and the other months' metabolic peaks (p < 0.05) in the treatment group although no differences emerged in the untreated group. These data suggest that INFbeta-1a has a favorable effect on restoration of metabolites in MS lesions.
authors.affiliation: Department of Neurology, Faculty of Medicine, Baskent University, Ankara, Turkey.
authors.forename: Münire Kilinç
authors.initials: MK
authors.lastname: Toprak
authors.forename: Banu
authors.initials: B
authors.lastname: Cakir
authors.forename: E Meltem Kayahan
authors.initials: EM
authors.lastname: Ulu
authors.forename: Zübeyde
authors.initials: Z
authors.lastname: Arat
authors.forename: Ulkü Sibel
authors.initials: US
authors.lastname: Benli
authors.forename: Ufuk
authors.initials: U
authors.lastname: Can
authors.forename: Muhtesem
authors.initials: M
authors.lastname: Ağildere
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000328:Adult; D001224:Aspartic Acid / Q000031:analogs & derivatives / Q000032:analysis / Q000378:metabolism; D015415:Biomarkers / Q000032:analysis / Q000378:metabolism; D001931:Brain Mapping; D002490:Central Nervous System / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D002794:Choline / Q000032:analysis / Q000378:metabolism; D003401:Creatine / Q000032:analysis / Q000378:metabolism; D004185:Disability Evaluation; D005260:Female; D006801:Humans; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000008:administration & dosage*; D009682:Magnetic Resonance Spectroscopy / Q000379:methods*; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D009413:Nerve Fibers, Myelinated / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D017063:Outcome Assessment, Health Care / Q000379:methods; D010865:Pilot Projects; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000276:Adjuvants, Immunologic; D015415:Biomarkers; D001224:Aspartic Acid; D016899:Interferon-beta; C000179:N-acetylaspartate; D003401:Creatine; D002794:Choline; D000068556:Interferon beta-1a